Monday, March 28, 2011

How a Specialty Pharmaceutical Company Leads the Way; Phase III Clinicals for the Only
Product Currently Addressing Female Sexual Dysfunction

March 28 , 2011 - (Investorideas.com newswire.com) Investorideas.com, an investor research
portal covering leading sectors including biotech stocks and pharma stocks, features an exclusive
Q&A interview and update with Mr. Stephen M. Simes, President and Chief Executive Officer of
BioSante Pharmaceuticals.

Stephen M. Simes, discusses how specializing in a product for female sexual dysfunction and
leading in development with LibiGel® in Phase III clinicals, makes BioSante Pharmaceuticals
(NASDAQ: BPAX) a company to watch.

JMP Securities released a report this month with a price target of $5.00. Mr. Simes gives his
insight as the company’s leader as to why the future looks so bright.

BioSante Pharmaceuticals Interview

Q: Investorideas.com
As you move forward with development of LibiGel® and other products in the pipeline, is your
company able to execute in terms of funding and cash available ? – and up to what time period?

A: Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals
It is quite interesting that a full 13 years after Viagra was approved for treating men’s
sexual issues, women still do not have an approved product to treat their sexual health.
Today, BioSante is the only company in the world in Phase III clinical development for the
treatment of women’s sexual dysfunction, specifically hypoactive sexual desire disorder.
This represents a major opportunity for BioSante and women since we expect to be first to
market with our LibiGel which is in several Phase III studies.

Q: Investorideas.com
JMP Securities recently released research on your company as an “underfollowed and
undervalued microcap company” and has placed a $5.00 target price. They note “Our $5
price target is derived by applying a 5x multiple to our base case projection for LibiGel sales
of $422MM in 2016, discounted by 30% per year. “ Can you comment on their revenue
projections ?

A: Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals
We believe the market potential for products like LibiGel is over $1 billion. This is derived
from many factors including the fact that the erectile dysfunction market in the U.S. alone
is over $2 billion and the market for male testosterone products is over $1 billion.

Q: Investorideas.com
The Company recently reported financial results and a pipeline update . Can you give us a

summary of what the pipeline looks like outside of LibiGel® ?

A: Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals
Yes, we have a full pipeline of products. Elestrin is our already approved estrogen product for the
treatment of hot flashes in menopausal women and Bio-T-Gel is our male testosterone product.
We hope to announce an FDA submission of Bio-T-Gel in the near future. In addition, we have a
full portfolio of cancer vaccines in clinical trials.

About LibiGel® LibiGel® is a gel formulation of testosterone in development that is quickly
absorbed through the skin after a once-daily application of a pea-sized dose of gel on the upper
arm, delivering testosterone to the bloodstream evenly over time and in a non-invasive and
painless manner. Though generally characterized as a male hormone, testosterone also is
present in women and its deficiency has been found to decrease libido or sex drive. In addition,
studies have shown that testosterone therapy can increase bone density, raise energy levels and
improve mood, in addition to boosting sexual desire and activity.

Currently, BioSante is conducting three Phase III clinical studies to demonstrate the safety
and efficacy of LibiGel to increase sexual desire and satisfying sexual events and to decrease
distress associated with the decreased desire. Two Phase III safety and efficacy trials that are
underway are randomized, double-blind, placebo-controlled trials which will enroll approximately
500 surgically menopausal women each for six-months of treatment. BioSante is conducting
these trials under an FDA agreed special protocol assessment (SPA). In addition, BioSante has
another SPA agreement with the FDA related to treatment of naturally menopausal women.
The SPA process and agreement confirms the FDA’s position that FSD and HSDD are true
conditions that women experience, with measurable endpoints, that can be evaluated and which
deserve therapeutic options. It also affirms that the FDA agrees that the LibiGel Phase III safety
and efficacy clinical trial design, clinical endpoints, sample size, planned conduct and statistical
analyses are acceptable to support regulatory approval. Further, it provides assurance that these
agreed measures will serve as the basis for regulatory review and the decision by the FDA to
approve an NDA for LibiGel.

About BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX)
BioSante (NASDAQ: BPAX) is a specialty pharmaceutical company focused on developing
products for female sexual health and oncology. BioSante’s lead products include LibiGel®
(transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is
in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special
Protocol Assessment. BioSante’s first FDA-approved product is Elestrin™ (estradiol gel)
indicated for the treatment of hot flashes associated with menopause, marketed in the U.S.
by Azur Pharma, BioSante’s licensee. BioSante also is developing a portfolio of cancer
vaccines, four of which have been granted Orphan Drug designation, and are currently in
several Phase II clinical trials. Other products are Bio-T-Gel™, a testosterone gel for male
hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical
development using BioSante patented technology. Additional information is available online at:
www.biosantepharma.com.

Visit the company profile on Investorideas.com: http://www.investorideas.com/CO/BPAX/
Or the company website www.biosantepharma.com to learn more about BioSante.

Request News & Updates from BioSante (NASDAQ: BPAX) on the Investorideas.com sign up
page: http://www.investorideas.com/Resources/Newsletter.asp

Recent Research

JMP Securities

We are initiating coverage on BioSante Pharmaceuticals with a Market Outperform rating
and price target of $5. We view BioSante as an underfollowed and undervalued microcap
company with a late-stage development asset that has better than average clinical risk.
BioSante's lead product candidate is LibiGel, a proprietary formulation of testosterone delivered
through the skin being developed for the treatment of female sexual dysfunction, for which there
is currently no approved therapy. We believe that with clarity emerging on timelines for key value-
driving LibiGel catalysts, institutional interest will increase and the market inefficiency in the
current valuation can begin to resolve. Our $5 price target is derived by applying a 5x multiple to
our base case projection for LibiGel sales of $422MM in 2016, discounted by 30% per year.
Full report :
http://www.investorideas.com/CO/BPAX/news/Initiating-Coverage-031611.pdf

About InvestorIdeas.com:

InvestorIdeas.com is a leading global investor and industry research resource portal specialized
in sector investing covering over thirty industry sectors and global markets including China,
India, the Middle East and Australia. Our leading biotech portal within our content umbrella,
www.BiotechIndustryStocks.com, covers the biotech/pharma sector for independent investors
with company profiles, news and stock directories.

Disclaimer: The following BioSante Pharmaceuticals, Inc company profile is a paid for submission (one thousand per
month) Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation
to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy
of information presented. All Information relating to featured companies is sourced from public documents and/ or the
company and is not the opinion of our web sites. This site is currently compensated by featured companies, news
submissions, company profile submissions and online advertising. http://www.investorideas.com/About/Disclaimer.asp
Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp

Forward-Looking Statements

To the extent any statements made in this news release deal with information that is not historical, these are forward-
looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are
not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future
operations and products, the timing of anticipated regulatory submissions and other statements identified by words such
as "will," "potential," "could," "can," "believe," "intends," "continue," "plans," "expects," "anticipates," "estimates," "may,"
other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that
are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different
than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties
and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other
approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success
of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these
and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities
and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on
Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante
undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future
events or otherwise.

For info about BioSante Pharmaceuticals, Inc

Contact:
For Investors:

The Trout Group LLC
Tricia Swanson
(646) 378-2953; tswanson@troutgroup.com

For Additional Information about Investorideas.com:

C Van Zant: 800-665-0411 – cvanzant@investorideas.com

Source – Investorideas.com
Energy Stocks to Watch for March 28th; (OTCBB: AAPH), (NASDAQ:TNGS), (NASDAQ:IVAN), (OTCBB: UTOG)


Point Roberts, WA - March 28, 2011 (Investorideas.com Energy Newswire) - InvestorIdeas.com, a leader in sector research for investors including energy stocks, reports on oil and gas stocks to watch March 28th.
Oil closed at $105.05 -0.35 -0.33%. Spreading unrest across the Middle East keeps oil above US$100. US stocks showed gains on Friday due to corporate earnings and improved economic data. Oil prices are a wild card in terms of how high it will go and at what point it starts to hurt the economic growth.
One way for investors to play the rising oil prices is to trade stocks within the sector.
Energy stocks to watch include American Petro-hunter Inc (OTCBB: AAPH), Halliburton Company (NYSE: HAL), ATP Oil & Gas Corp. (NASDAQ: ATPG), and Ivanhoe Energy Inc. (NASDAQ: IVAN).
Sector Snapshot: (Trading at close March 25)
  • American Petro-hunter Inc (OTCBB: AAPH) trading at $0.35, up 0.02 (6.06%)
  • Titan Oil & Gas, Inc. (OTCBB: TNGS) trading at $1.30, up 0.02 (1.56%)
  • Ivanhoe Energy Inc. (NASDAQ: IVAN) trading at $2.97, up 0.02 (0.68%)
  • UNIONTOWN ENERGY INC, (OTCBB: UTOG) tradingat $1.71 on over 5 Million shares in volume
Oil and Gas Stocks News
American Petro-hunter Inc (OTCBB: AAPH) Recent Press
Latest News:
Oil Stocks News Alert; American Petro-Hunter (OTCBB: AAPH) Adds 2,000 Acres of Prime Horizontal Well Opportunities at North Oklahoma Project
"SCOTTSDALE, AZ - March 25, 2011 (Investorideas.com energy newswire) - American Petro-Hunter, Inc. (OTC.BB:AAPH) ("American Petro-Hunter" or the "Company") today is pleased to announce that the Company has acquired a majority working interest in an additional 2,000 acres of lands located in Payne County, Oklahoma. The acreage augments the Company's holdings at the North Oklahoma Project to 3,400 total gross acres.
With this recent acquisition, the Company has designated the new lands as the "Ripley Prospect" and the original lands as the "Yale Prospect," with both areas held as regional components of the North Oklahoma Project. The newly acquired Ripley acreage is located in a key area of an emerging horizontal drilling play where over 100 foot thick sections of Mississippi Formation are currently being aggressively exploited by regional players deploying laterally drilled, horizontal wells.”
Full News at¨http://www.investorideas.com/CO/AAPH/news/2011/03251.asp
About American Petro-Hunter, Inc. (OTC.BB:AAPH )
The Company is a goal-oriented exploration and production (E&P) Company aiming to become an intermediate level oil and gas producer within 12 months. The Company is in production at the Poston Project in Trego County Kansas and the North Oklahoma Project. With the achievable target of becoming a 1000 BOE producer as our goal, American Petro-Hunter is actively on the "hunt" for domestic petroleum assets. Visit us at: www.americanpetrohunter.com
Visit the AAPH showcase profile on Investorideas.com:
http://www.investorideas.com/CO/AAPH/
UNIONTOWN ENERGY INC, (OTCBB: UTOG) Recent Press
Latest News:
UnionTown Energy Inc. Announces Major Authorized Stock Reduction " BILLINGS, MT-- - 03/25/11 - UnionTown Energy Inc. (OTC.BB: UTOG) today reported the initiation of a reduction in authorized capital to 300 million common shares to provide strong shareholder protection and exceptional corporate growth. The Company is focused on shareholder value and views this corporate action as a major step in propelling Uniontown Energy towards its goal of becoming a successful major oil and gas entity.
The Company is discussing agreements with counsel for the immediate CUSIP and a name change to accommodate the aggressive corporate moves to acquisition and production. This may result in delivery of all Union Energy Inc. stock to the Company's current transfer agent on an immediate delivery protocol.”
Full News at: http://finance.yahoo.com/news/UnionTown-Energy-Inc-iw-1382215689.html?x=0&.v=1
Ivanhoe Energy Inc. ( NASDAQ: IVAN) Recent Press
Latest News:
Ivanhoe Energy reports 2010 financial results and operational highlights
" CALGARY, March 17 Ivanhoe Energy Inc. (NASDAQ:IVAN) today announced summary financial results and operating highlights for the year ended December 31, 2010. All figures reported are in US dollars unless otherwise noted. Ivanhoe Energy has filed its annual report on Form 10-K for the year ended December 31, 2010.
Highlights
Ivanhoe Energy marked a major advance towards commercial production at its Tamarack Project with the submission of its regulatory application to the Government of Alberta in November 2010.
Subsequent to year end, Ivanhoe Energy announced that probable plus possible reserves were recognized for the Tamarack Project. GLJ Petroleum Consultants of Calgary assigned estimated (2P) bitumen reserves of 176 million barrels and probable plus possible (3P) bitumen reserves of 220 million barrels and probable to Tamarack. Along with the reserves additions, the independent 2010 evaluation recognized 345 million barrels of best estimate contingent resource.”
Full News at: http://finance.yahoo.com/news/Ivanhoe-Energy-reports-2010-prnews-2576133429.html?x=0&.v=28
Titan Oil & Gas, Inc. ( OTCBB: TNGS) Recent Press
Latest News:
Titan Oil & Gas Provides Update on Production Opportunities
"Press Release Source: Titan Oil & Gas Inc. On Tuesday March 22, 2011
LAS VEGAS , NV-- - Titan Oil & Gas, Inc. (OTC.BB: TNGS) ("Titan" or "the Company") is pleased to provide an update on recent corporate developments.
In the past thirty days, several groups have approached Titan with a large number of partnership, acquisition, and joint venture opportunities.
Titan has completed its initial review of approximately twenty properties and as a result of its due diligence process, has identified three high-priority targets. Each target has the potential for immediate production and would provide the company with near-term cash-flow.”
Full News at: http://finance.yahoo.com/news/Titan-Oil-Gas-Provides-Update-iw-481847867.html?x=0
About InvestorIdeas.com:
Sign up for free investor stock alerts :
http://www.investorideas.com/Resources/Newsletter.asp
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including mining and gold stocks, in addition to global markets including China, India, the Middle East and Australia. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires.
About our Oil and Gas portal:
Research more energy stocks:
Visit the oil and gas stocks directory listing publicly traded stocks from multiple global stock exchanges including TSX, ASX, OTC, NASDAQ and NYSE.
http://www.investorideas.com/OGSN/Stock_List.asp
www.OilandGasStocksNews.com is a global meeting place for investors and industry following the energy sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our oil and gas and natural gas stock directories. Investors can also follow energy commentary from energy expert Karl Miller.
Disclaimer: The following American Petro-Hunter Inc news is paid for by third party on behalf of showcase energy stock AAPH ( averaging two thousand per month). Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer:http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
For info on American Petro-hunter Inc ( OTCBB: AAPH) contact the company IR directly.
For info on Investorideas.com
Contact:
C Van Zant: 800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com


Visit the AAPH showcase profile at Investorideas.com
Request News and Info on AAPH
Disclosure, Disclaimer/ AAPH is a paid advertising client on Investorideas.com.
American Petro-hunter Inc. (AAPH.OB) Oct 2010 - one month showcase energy stock on Investorideas.com and energy portals and blogs (three thousand per month)

Friday, March 25, 2011

Energy Stocks News; American Petro-Hunter (OTCBB: AAPH) Adds 2,000 Acres of Prime Horizontal Well Opportunities at North Oklahoma Project

SCOTTSDALE, AZ � March 25, 2011 (Investorideas.com energy newswire) - American Petro-Hunter, Inc. (OTC.BB:AAPH) ("American Petro-Hunter" or the "Company") today is pleased to announce that the Company has acquired a majority working interest in an additional 2,000 acres of lands located in Payne County, Oklahoma. The acreage augments the Company's holdings at the North Oklahoma Project to 3,400 total gross acres.
With this recent acquisition, the Company has designated the new lands as the "Ripley Prospect" and the original lands as the "Yale Prospect," with both areas held as regional components of the North Oklahoma Project. The newly acquired Ripley acreage is located in a key area of an emerging horizontal drilling play where over 100 foot thick sections of Mississippi Formation are currently being aggressively exploited by regional players deploying laterally drilled, horizontal wells.
Surrounding the Ripley Prospect, numerous lease holdings are under development by Tulsa-based Calyx Energy, a private company. To date, Calyx has drilled 3 horizontal wells on leases within a mile and a quarter (1� mile) south of the Ripley block and, of major significance to the Company, the nearby C&N 25-1H well has been speculated to have had initial production rates (I.P.) of 1,000 barrels per day (BPD). Calyx also has plans for further wells immediately north of our Ripley Prospect holdings and is currently exploiting prospects on over 40,000 acres in central and eastern Oklahoma.
The 2,000 acre Ripley Prospect block is now part of the central focus of the Company's 2011 development plan. A location for our first Mississippi horizontal has been engineered and proposed. The 1,500 to 4,000 foot lateral will drill down and along the Mississippi which sits directly over the Woodford Shale. The lease block would allow, if successful, for the drilling of 5 horizontals on 320 acre parcels. Further information will be released regarding potential spud dates and particulars on the play.
Company President Robert McIntosh states, "We are very pleased to have added this encouraging and very interesting horizontal Mississippi play to the North Oklahoma Project. With the new drilling combined with our existing lands encompassing both Woodford and Mississippi prospects, we have secured sufficient acreage to drill many horizontal and vertical wells in 2011. If we are successful, we will rapidly move the Company forward to our stated production goals and targets."
Given the added expense of horizontal drilling, American Petro-Hunter has developed a prudent "watch & learn" approach based on the experiences of the well-funded major operators at the Yale Prospect area. As the drill programs currently under development by the major players adjacent to our Yale Prospect are not yet underway, the opportunity to quickly move into a proven and highly productive area less than 10 miles away at Ripley presented itself as a desirable near term opportunity. The Company will continue to explore and develop vertical wells in the Yale area and plans to immediately follow up the NOS227 well dependent on completion results.
About American Petro-Hunter, Inc. (OTCBB: AAPH)
The Company is a goal-oriented exploration and production (E&P) Company aiming to become an intermediate level oil and gas producer within 12 months. The Company is in production at the Poston Project in Trego County Kansas with new drilling activity and production underway at the North Oklahoma Oil Project. With the achievable target of becoming a 1000 BOE producer as our goal, American Petro-Hunter is actively on the "hunt" for domestic petroleum assets. Visit us at: www.americanpetrohunter.com
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of our exploration program at our properties and any anticipated future production. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with petroleum exploration and development stage exploration companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-KSB for the most recent fiscal year, our quarterly reports on Form 10-QSB and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
American Petro-Hunter, Inc.
Robert McIntosh
President & C.E.O.
To find out more about American Petro-Hunter, Inc. (OTC.BB:AAPH), visit our website at www.americanpetrohunter.com
Contact:
Investor Relations:
Mountainview IR Services, Inc.
1-888-521-7762
investors@americanpetrohunterinc.com
Visit the AAPH showcase profile at Investorideas.com
Request News and Info on AAPH
Disclosure, Disclaimer/ AAPH is a paid advertising client on Investorideas.com.
American Petro-hunter Inc. (AAPH.OB) Oct 2010 - one month showcase energy stock on Investorideas.com and energy portals and blogs (three thousand per month)
Electric Car Stocks Trading Alert; (OTCBB: EVCA), (NASDAQ: TSLA, (NASDAQ:AONE),
(Nasdaq:MXWL)

Maxwell Technologies, Inc. (Nasdaq:MXWL) trading up at $17.04, up 0.52 (3.15%)

March 25, 2011 (Investorideas.com renewable energy/green newswire) Investorideas.com a
leader in cleantech investor research, reports on electric car stocks and battery stocks trading for
March 25th. As markets give investors another positive trading day, the sector shows strength.
Oil is trading at $104.91 -0.69 -0.65 %, off for the day, but high enough to be a driving factor for
the alternative energy sector.

Electric Car Sector Snapshot
A123 Systems, Inc. (NasdaqGM: AONE) trading at $ 7.86, up 0.03 (0.38%) 12:55PM EDT
ENER1, Inc. (NASDAQ: HEV) trading at $ 2.96, up 0.05 (1.72%)
Ecotality, Inc. (NasdaqCM: ECTY) trading at $2.84, down 0.05 (1.73%) 11:45AM EDT
EVCARCO (OTCBB: EVCA)) trading at $ 0.0215
Maxwell Technologies, Inc. (Nasdaq:MXWL) trading up at $17.04, up 0.52 (3.15%) 12:59PM EDT
NRG Energy, Inc.(NYSE: NRG ) trading at $21.39, up 0.25 (1.18%) 1:03PM EDT
Tesla Motors, Inc. (NASDAQ: TSLA) trading at $ 22.85, up 0.52 (2.33%) 12:44PM EDT
UQM Technologies, Inc. (NYSE Amex: UQM) trading at $3.08, down 0.06 (1.91%) 1:04PM EDT

Market Snapshot
Dow 12,236.25 +65.69 +0.54%
Nasdaq 2,756.86 +20.44 +0.75%
S&P 500 1,317.14 +7.48 +0.57%
10 Yr Bond(%) 3.4240% +0.02
Oil 104.91 -0.69 -0.65%
Gold 1,434.80 0.00 0.00%

Company Snapshot

EVCARCO (OTC.BB:EVCA)- Green , Electric Cars and Natural Gas Vehicles
EVCARCO (OTC.BB:EVCA) (www.evcarco.com) is the first automotive retail group dedicated
to deploying a coast-to-coast network of environmentally friendly franchised dealerships and
vehicles. EVCARCO is bringing to market the most advanced clean technologies available in
plug-in electric, alternative fuel, and pre-owned hybrid vehicles.

Recent Industry News :
Environment Agency goes pure electric with Mitsubishi i-MiEV
25th March 2011 Print Email Share

After decades of experimentation, innovation and trials, the future of motoring is
here and today sees the Environment Agency take delivery of its first pure-electric
vehicle (EV) in a bid to reduce the organisation’s carbon footprint. The event coincides
with Climate Change Week which is aimed at demonstrating what can be done by
businesses and individuals to reduce CO2 and to encourage more people to act on
climate change.
Full news: http://www.easier.com/86402-environment-agency-mitsubishi-i-miev.html

Research electric car stocks and green auto stocks, lithium stocks - with the renewable

energy stocks directory Research over 1300 green stocks - Investors also have the option to
access the directory as part of the Investor Ideas Investors also have the option to access the
directory as part of the Investor Ideas Membership premium content that currently features
an additional 10 stock directories, including the water stocks directory and all cleantech stock

directories. http://www.investorideas.com/membership/

Investors - sign up for free stock alerts and investor news alerts
http://www.investorideas.com/Resources/Newsletter.asp

About Our Green Investor content:
Investorideas.com was on the of the first investor sites covering investing in water and renewable
energy stocks and has become a global go-to destination for investors researching the cleantech
sector, with stock directories, company news, commentary from experts, research reports and
industry resources and links. Investors can follow solar stocks commentary on our site with solar
expert, J. Peter Lynch.

Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed
as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly,
but we offer no guarantees as to the accuracy of information presented. All Information relating
to featured companies is sourced from public documents and/ or the company and is not the
opinion of our web sites. Disclosure: Investorideas is compensated by featured green companies
EVCARCO (OTCBB: EVCA) is a showcase stock at Investorideas.com and compensated the site
500,000 144 shares in lieu of cash compensation.

To become a showcase company, contact us below.
For more information contact:
Email: dvanzant@investorideas.com or Cali at cvanzant@investorideas.com
Source: www.Investorideas.com
Gold Stocks; Gold Bullion (TSX-V: GBB) Appoints Ronald Goguen Sr. to The Board Of Directors

Vancouver, British Columbia - March 24, 2011 (Investorideas.com Mining stocks Newswire) - Mr. Frank J. Basa reports: Gold Bullion Development Corp. (CDNX:GBB.V) (Other OTC:GBBFF.PK) (the "Company" or "Gold Bullion") is pleased to announce the appointment of Ronald Goguen, Sr. to the Company�s Board of Directors.
Mr. Goguen is the founding shareholder of Landdrill International Inc.'s predecessor company, and has been President and Chief Executive Officer of Landdrill since taking it public in March 2006. Mr. Goguen purchased his first exploration drilling company, Ideal Drilling, in 1980. In 1981, he added a second exploration drilling company and increased sales and net income significantly. Those companies were combined to become Major Drilling Group International Inc., a publicly traded company that has traded on the Toronto Stock Exchange since March 1995. Mr. Goguen served as President and Chief Executive Officer until 2000, and during this time was a key driving force in building Major Drilling into one of the largest mineral drilling service companies in the world (33 operations in 15 countries).
Since leaving Major Drilling in 2000, Mr. Goguen has served as the President of Royal Oaks Real Estates Inc. and Royal Oaks Golf & Country Club. During 2006 Mr. Goguen was appointed Chairman of the Board of Directors for Beaver Brook Antimony Mine Inc., and he remained so until bringing its operation into production during early 2008. Beaver Brook is the largest antimony mine outside of China. Now that this company is operating, management has been put in place to carry on its operation and Mr. Goguen remains one of its directors. Mr. Goguen is currently a member of the board of directors of Northeast Bancorp, Saratoga Capital Management and Colibri Resource Corporation. During 1995 Mr. Goguen was named Atlantic Canada's entrepreneur of the year as presented by the Governor General of Canada.
About Gold Bullion Development Corp.
Gold Bullion Development Corp. is a TSX Venture listed junior natural resource company focusing on the exploration and development of its Granada Gold Property near Rouyn-Noranda, Quebec, and its high grade Castle Silver Mine in Gowganda, Ontario.
For more information on Gold Bullion Development Corp. (TSX-V: GBB, OTC PK: GBBFF), visit our web site: http://www.GoldBullionDevelopmentCorp.com
Frank J. Basa, P.Eng.
President and Chief Executive Officer
For further information contact:
Frank J. Basa, P.Eng., President and CEO: 1-416-625-2342
Roger Thomas, Director: 1-613-292-2438
Progressive Investor Relations (Canada) Tel (604) 689-2881 or email info@progressive-ir.com
Torrey Hills Capital (United States) Tel (858) 456-7300
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming work programs, geological interpretations, receipt of property titles, potential mineral recovery processes, etc. Forward-looking statements address future events and conditions and therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.
Visit the GBB showcase profile at Investorideas.com
Request News and Info on GBB
Disclosure, Disclaimer/ GBB is a paid advertising client on Investorideas.com and our mining portals.
Emerging Opportunities in Biodefense; An interview with Aethlon Medical (OTCBB: AEMD)

CEO, Jim Joyce

Point Roberts, WA. March 25, 2011 – Investorideas.com, a leader in sector research including

biotech and biodefense stocks, presents an interview with Jim Joyce, CEO of Aethlon Medical

(OTCBB: AEMD).

InvestorIdeas: What opportunities exist for small organizations that want to participate in

the emerging biodefense industry?

Jim Joyce, CEO of Aethlon Medical (OTCBB: AEMD)

Multiple opportunities have recently surfaced for small organizations with innovative

countermeasures against bioterror threats, and more are expected in the near future. As an

example, Freemind Group, an industry advisory organization reported this week that they are

witnessing a dramatic and unprecedented surge in biodefense and infectious disease funding

opportunities from various government institutes. They anticipate that funding applications

submitted during the coming months of May, June, and July alone will result in cumulative awards

of approximately $500,000,000.00. In fact, some of these awards are not capped and can exceed

$50,000,000 for clinical trial support. For small organizations, such non-dilutive awards offer to

transform business capabilities and reward patient shareholders.

InvestorIdeas: That’s certainly exciting, but how can small organizations like Aethlon

Medical compete against big pharma for such awards?

Jim Joyce, CEO of Aethlon Medical

In reality, both big pharma and large biotechnology players have demonstrated little interest

in responding to these programs. As a result, government agencies are primarily reliant on

innovation stemming from research advanced by small organizations, which from a historical

basis, is likely to be the principal source of innovation anyway. Still, these programs do not

exist to solely support research. Recently created agencies like the Biomedical Research and

Development Authority (known as BARDA) provide support for post R&D activities including

clinical studies, manufacturing, and other activities that may be required to transition a candidate

treatment countermeasure into the strategic national stockpile.

InvestorIdeas: Do you feel Aethlon Medical is positioned to benefit from these programs?

Mr. Joyce: I feel we are extremely well positioned to benefit as government policies to protect

against bioterror and pandemic threats have been redefined to focus support towards broad-

spectrum countermeasures that are able to address multiple pathogen threats. Based on pre-

clinical and clinical data, we believe our Hemopurifier® is the most advanced and perhaps only

true broad-spectrum countermeasure. While traditional therapeutics often struggle to address

multiple strains of the same pathogen, third party researchers have demonstrated that our

Hemopurifier® captures different species of many of the most deadly viral threats known to man.

These include Dengue, Ebola, and Lassa Hemorrhagic Viruses, West Nile Virus, H5N1 Avian

Influenza Virus, the 2009 H1N1 Influenza Virus, the reconstructed Spanish Flu of 1918, and

Monkeypox Virus, which is the primary model for testing treatments against human Smallpox

infection.

InvestorIdeas: Have you conducted any human studies with your Hemopurifier®

Jim Joyce, CEO of Aethlon Medical

Yes, we have advanced our technology into human studies, which demonstrated safety and the

observation of significant viral load reductions in both hepatitis-C and HIV infected individuals

without the administration of antiviral drug therapies. We are now advancing a clinical program

whose objective is to utilize our Hemopurifier® as an adjunct strategy to improve the benefit

of hepatitis-C standard-of-care drug therapy without adding drug toxicity and interaction risks.

We are quite excited about this clinical program, as therapeutic filtration of hepatitis-C from

plasma has previously proven to have a remarkable effect in improving treatment outcomes

when combined with drug therapy.

opportunity, I feel confident that we are advancing a leading broad-spectrum therapeutic strategy

to address viral threats, and that our strategy fulfills strategic objectives recently mandated by

our government.

treatment countermeasures that may also have mainstream commercial market applications in

disease conditions such as hepatitis-C, HIV, and cancer.

InvestorIdeas: Is Aethlon Medical currently pursuing any contract or grant opportunities?

Jim Joyce, CEO of Aethlon Medical
Yes. In the coming days we will submit a formal response to a military program opportunity
entitled “Dialysis Like Therapeutics”. The stated goal of this program is the creation of a medical
device that would save the lives of thousands of military patients each year. While our response
is challenging, it has also been rewarding as we have attracted several groups to partner and
participate in our submission. Once our response is in, we will then convene with our advisors to
determine the next contract opportunity to focus our efforts towards.

InvestorIdeas: In closing, is there any advice you would provide to other organizations

that might be interested in participating in the biodefense and pandemic threat industry?

Jim Joyce, CEO of Aethlon Medical

By nature, the opportunity to address the looming threat of biological weapons and naturally

Regardless, as it specifically relates to our biodefense

We also benefit from a policy shift that no longer precludes the support of

emerging pandemic threats will be enduring and the industry is still very young. However, my

advise for small organizations is to be sure they have therapeutic strategies in place to address

established disease conditions with real commercial markets before venturing into a field where

targeted disease conditions may or may not emerge and the primary source of support is

government funding.

About Aethlon Medical (OTCBB: AEMD)

At Aethlon Medical, we create revolutionary devices to address infectious disease and cancer.
Our devices are designed to be novel platform solutions that fill therapeutic voids or aid in
disease diagnosis and monitoring.

Our Hemopurifier® is the first medical device to selectively target the removal of infectious
viruses and immunosuppressive proteins from the entire circulatory system. We recently
discovered that our Hemopurifier® captures tumor-secreted exosomes that suppress the immune
system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly
inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in cancer
care. By eliminating this mechanism, we believe our Hemopurifier® can fill an unmet clinical need
and provide the benefit of an immune-based therapy without adding drug toxicity or interaction
risks to established and emerging treatment strategies.

Human studies have documented the ability of our Hemopurifier® to safely reduce viral load
in both Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients
without the administration of antiviral drugs. However, our initial clinical and commercialization
focus is to establish our Hemopurifier® as an adjunct therapy to enhance the benefit of both
infectious disease and cancer treatment regimens. In this regard, we plan to commercialize
our Hemopurifier® in India as we advance our clinical strategies in the United States and the
European Union. In vitro studies conducted by government and non-government research
institutes have also verified that our Hemopurifier® has broad-spectrum capabilities against
bioterror and emerging pandemic threats. These studies have confirmed the capture of Dengue
Hemorrhagic Virus, Ebola Hemorrhagic Virus, Lassa Hemorrhagic Virus, West Nile Virus, H5N1
Avian Influenza Virus, 2009 H1N1 Influenza Virus, the reconstructed Spanish Flu of 1918 Virus,
and Monkeypox Virus, which serves as a model for human Smallpox infection.

As a therapeutic device, the Hemopurifier® provides us with a pipeline into four significant market
opportunities:
1. Cancer: A treatment candidate to improve patient responsiveness to established cancer
therapies by removing immunosuppressive exosomes from circulation.
2. Hepatitis-C Virus (HCV): As an adjunct therapy to accelerate viral load reduction at the outset
of standard of care drug regimens.
3. Human Immunodeficiency Virus (HIV): Provides a potential therapeutic option for HIV-infected
individuals to manage disease progression once they become resistant to antiviral drug regimens.
4. Bioterror and Pandemic Threats: Represents the most advanced broad-spectrum strategy to
address untreatable bioterror and emerging pandemic threats.

The Hemopurifier® is an expansive multi-patented platform technology whose mechanism
of action can be leveraged to provide therapeutic, diagnostic, and biomarker discovery
solutions. As a therapeutic, the Hemopurifier® is a single-use disposable cartridge designed
for implementation within the established infrastructure of dialysis machines and other blood
circulatory pumps already located in hospitals and clinics worldwide.

In design, our Hemopurifier® is a selective filtration device containing affinity agents that
tightly bind to high-mannose structures unique to the surface of exosomes produced by cancer

and glycoproteins residing on the envelope of viruses. These agents are immobilized around
approximately 2800 porous hollow fibers that run the interior length of our device. The resulting
design provides us the novel ability to separate both exosome and viral targets away from blood
cells so they can then be selectively and permanently removed from the circulatory system. In
application, blood circulation is established into the Hemopurifier® via a catheter or other blood
access device. Once blood flow has been established, treatment benefit is immediate as the
entire circulatory system can pass through the Hemopurifier® in as little as 15 minutes.

Our wholly owned subsidiary, Exosome Sciences, Inc. (ESI) is focused on the development of
exosome-targeted products and services that improve cancer diagnosis, provide post-treatment
cancer surveillance, and aid in the discovery of biomarkers that allow doctors to optimize patient
therapy. Additional information regarding Aethlon Medical and Exosome Sciences can be
accessed online at www.aethlonmedical.com.

Certain of the statements herein may be forward-looking and involve risks and uncertainties.
Such forward-looking statements involve assumptions, known and unknown risks, uncertainties
and other factors which may cause the actual results, performance or achievements of Aethlon
Medical, Inc. to be materially different from any future results, performance, or achievements
expressed or implied by the forward-looking statements. Such potential risks and uncertainties
include, without limitation, the company's ability to commercialize its Hemopurifier® in India,
capability of the Hemopurifier® to reduce viral loads and other disease conditions or to identify or
treat disease conditions such as cancer or Hepatitis-C, including the ability to capture exosomes
and the impact that potential ability may have on disease conditions, the Company's ability to
raise capital when needed, the Company's ability to complete the development of its planned
products, the ability of the Company to obtain FDA and other regulatory approvals permitting
the sale of its products, the Company's ability to manufacture its products either internally or
through outside companies and provide its services, the impact of government regulations, patent
protection on the Company's proprietary technology, product liability exposure, uncertainty of
market acceptance, competition, technological change, and other risk factors. In such instances,
actual results could differ materially as a result of a variety of factors, including the risks
associated with the effect of changing economic conditions and other risk factors detailed in the
Company's Securities and Exchange Commission filings.

Contacts:
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com

About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized
in sector investing, including biotech stocks with its portal BiotechIndustryStocks.com.

Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/
Stock_List.asp

Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/AEMD

Get added to the company’s news alerts:
http://www.investorideas.com/Resources/Newsletter.asp

Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research
Our sites do not make recommendations, but offer information portals to research news,
articles, stock lists and recent research. Nothing on our sites should be construed as an offer or

solicitation to buy or sell products or securities. This site is currently compensated by featured
companies, news submissions and online advertising. AETHLON MEDICAL INC (OTC BB:
AEMD) Showcase biotech, biodefense and defense stock on Investorideas.com ($one thousand
five hundred per month, $five thousand per month in 144 stock) Effective March 15, 2011

800-665-0411 – dvanzant@investorideas.com
Source - Investorideas.com

Thursday, March 24, 2011

Gold Stock Running Fox (TSX-V: RUN) Trading up over 8% on Recent News; Follow on to Yesterday's Trading

POINT ROBERTS, Wash., March 24, 2011 - www.InvestorIdeas.com, a leader in sector research for investors including mining stocks, features a gold stock trading alert on Running Fox Resources, (TSX-V:RUN) (US OTC:RFXRF) (FRANKFURT:C8Q). Following yesterdays news on its New Mexico project drilling, the stock was up 10%. The stock is trading this morning at $ 0.26, up another 0.02 (8.33%).
Investorideas.com Mining Newswire Running Fox (TSX-V:RUN) (US OTC:RFXRF) (FRANKFURT:C8Q) is a Canadian growth-oriented resource company with mineral projects including US uranium and Canadian gold properties, oil and gas assets, and oilfield service operations.
www.foxgold.ca
Recent News:
Running Fox Resource Corp. New Mexico Project Drilling
Steve Schurman, CEO, Director, reports:
Running Fox Resources, (TSX-V: RUN) ( US OTC: RFXRF) ( FRANKFURT: C8Q)
The Company reports that diamond drilling has now started on a multi-hole drill program on Running Fox''s 100 % owned New Mexico project located south of Grants, New Mexico. Strategic Resources has optioned the property and is drilling to earn a 50 % interest, and may earn up to a 60 % interest upon delivery of a bankable mine feasibility study.
Running Fox also reports that its acquisition of the remaining 50 % of the Brett Gold and Silver Project is being finalized and Company plans to announce completion soon.
On Behalf of the Board of Directors, Steven Schurman
Running Fox Resource Corp.
1 604 725 8868
www.foxgold.ca
About our Mining Portals:
www.Gold-MiningStocks.com and www.MiningSectorStocks.com are research portals within the InvestorIdeas.com content umbrella, featuring industry and stock news, exclusive articles and financial columnists, audio interviews and podcasts, investor conferences, blogs, and a directory of over 1200 mining stocks.
Gold and Mining Stocks: over 1200 listed stocks
Mining and Gold Stocks Directory - Global Mining and Gold Stocks Directory in PDF format lists over 1200 publicly traded mining companies. Mining and metals investors can research gold and mining stocks with the mining stocks directory, featuring Gold Stocks, Silver Stocks, Uranium Stocks, Copper Stocks, Zinc Stocks and Precious Metals TSX, TSX Venture, OTC, NASDAQ, AMEX, NYSE, ASX, AIM and other leading Stock Exchanges.
http://www.investorideas.com/Gold_Stocks/Stocks_List.asp
Sign up for the free investor news letter and get stock alerts in leading sectors! http://www.investorideas.com/Resources/Newsletter.asp
About InvestorIdeas.com:
Investor Ideas is a global financial media online destination specialized in sector investing content.
Disclosure: The following news is paid for and /or published as information only for our readers. Running Fox Resource Corp. (TSX.V: RUN) for three days or press release services (seven hundred)
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp
For Additional Information
800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com
"Wall Street Economics is Bad for Innovation"- Levine's MicroCap Investor
Functional Inspiration Blog: Money and Innovation in the Microsphere, by Josh Levine

Wall Street Economics is Bad for Innovation
March 23, 2010
By Josh Levine
Learn more about subscribing to Levine�s MicroCap Investor:
http://www.levinesmicrocapinvestor.com/subscriptions/order/
The institutionalization of finance has been good for Wall Street power brokers, enabling them to concentrate control and profits. But it has done absolutely nothing to improve the environment for small innovative companies seeking to raise $5 million, $20 million, or $50 million. In fact, it has sucked capital away from emerging growth firms and into a mundane mosaic of investments – everything from securitized mortgages to ETFs of every stripe.
The matra of "bigger is better" means investment bankers, hedge funds, venture capitalists and others can earn bigger fees, but it creates a huge vacuum in the system. Too much risk (and intellectual) capital is being channeled into casino-like trading and a range of investment gimmicks rather than serving growth companies and research and development.
The model for funding small innovative firms has been broken for many years, and the economic and opportunity costs are killing us.
Until a better system emerges, many of the most challenging economic problems faced by the United States, including terminal unemployment, decline in leadership of innovation-driven markets, and shrinking capital markets for emerging growth companies, may never be fully reversed.
One of the most effective ways to improve the situation is by changing the incentive system for financing small technology companies.
As two senior advisors at Grant Thornton -- Edward Kim and David Weild -- correctly point out, markets have become inhospitable to smaller private companies looking to raise less than $50 million.
CFO magazine, reporting on their recent testimony for a U.S. congressional subcommittee, says:
"The main cause, as they see it, is lower trading fees, stemming first from online brokerages and new order-handling rules in the late 1990s, and then from decimalization, Sarbanes-Oxley, and the global research analyst settlement separating research from banking. Given the lower fees, it no longer makes economic sense for investment banks to support small-company IPOs with capital and research. Kim says that small companies 'are not a product anymore; they're just food for Goldman Sachs's real clients'— hedge funds looking for quick gains through IPOs…"
Without a major revision of the economic incentives for funding and supporting small companies, we're stuck with a busted system for financing innovation. And while the passage of the Small Company Capital Formation Act of 2011 (a bill that would increase the amount of money companies can raise in the public markets through Reg A transactions from $5 million to $50 million) would help the situation, it will fall far short of what's really needed.
According to Kim, raising the limit to $50 million "would be a positive step that would reduce some red tape, and one that I think Congress will pass, but it's just one step of many that would be needed. I truly believe that without a completely different market model, we won't fix the problems."
Clearly, there is no simple cure for what ails innovation financing. While a new Reg A limit would at least be a first step towards improving market conditions for the companies that have the potential to transform the U.S. economy, there's much more that can, and should, be done.
In an upcoming entry for Functional Inspiration, I will explore some initiatives that could create better opportunities for smaller companies to access capital and accelerate the development of emerging technologies into the marketplace.
Subscribe to Functional Inspiration Blog http://www.levinesmicrocapinvestor.com/RSS/Articles.xml
MicroCap Investor delves deep into the world of small stocks to identify big winners. Levine targets innovative companies on the path of the new and revolutionary, developing technologies that disrupt entrenched markets to create tremendous value.
About Josh Levine and Levine's MicroCap Investorwww.levinesmicrocapinvestor.com
Josh Levine has 25 years of senior-level experience in analyzing technology trends and investing in top-performing micro- and small-cap stocks. He excels at assessing management teams and evaluating new innovations and their impact on corporate valuations.
In 2002 he joined independent investment-research boutique ChangeWave Research, where he was editor of ChangeWave MicroCap Investor since 2004, becoming Levine's MicroCap Investor in 2010. He has been editor of the flagship ChangeWave Investing since 2007.
Levine is also senior analyst for ChangeWave Research. Through its survey network comprised of 25,000 members, ChangeWave tracks the rate of change in corporate and consumer demand trends and provides the results through an institutional research subscription service. Its macroeconomic research is among the best on Wall Street.
More on Levine's bio: http://www.levinesmicrocapinvestor.com/aboutus/
Learn more about subscribing to Levine's MicroCap Investor: http://www.levinesmicrocapinvestor.com/subscriptions/order/
InvestorIdeas.com is partnered with Josh Levine and MicroCap Investor as part of its mission to provide investors with research tools to explore the world of small stocks. The InvestorIdeas.com team operates this web site and manages the administration and marketing for MicroCap Investor.
InvestorIdeas.com is a leading investment and industry research portal, with resources covering high-growth sectors including technology, biotech and cleantech.
Levine's MicroCap Investor
Contact us
admin@levinesmicrocapinvestor.com
800 665 0411

Wednesday, March 23, 2011

TSX Gold and Mining Stocks Alert; Running Fox (TSX-V: RUN); Trading up 10.20% on News on New Mexico Project

POINT ROBERTS, Wash., March 23, 2011 - www.InvestorIdeas.com, a leader in sector research
for investors, features a mining stock alert on Running Fox Resources, (TSX-V:RUN) (US
OTC:RFXRF) (FRANKFURT:C8Q) following news on its New Mexico project drilling released
today. The stock is trading is trading at $ 0.27, up 0.03 (10.20%).

Running Fox (TSX-V:RUN) (US OTC:RFXRF) (FRANKFURT:C8Q) is a Canadian growth-
oriented resource company with mineral projects including US uranium and Canadian gold
properties, oil and gas assets, and oilfield service operations.
www.foxgold.ca

Today’s News:
Running Fox Resource Corp. New Mexico Project Drilling

Steve Schurman, CEO, Director, reports:
Running Fox Resources, (TSX-V: RUN) (US OTC: RFXRF) (FRANKFURT: C8Q)

The Company reports that diamond drilling has now started on a multi-hole drill program on
Running Fox''s 100 % owned New Mexico project located south of Grants, New Mexico. Strategic
Resources has optioned the property and is drilling to earn a 50 % interest, and may earn up to a
60 % interest upon delivery of a bankable mine feasibility study.

Running Fox also reports that its acquisition of the remaining 50 % of the Brett Gold and Silver
Project is being finalized and Company plans to announce completion soon.

On Behalf of the Board of Directors, Steven Schurman
Running Fox Resource Corp.
1 604 725 8868
www.foxgold.ca

About our Mining Portals:
www.Gold-MiningStocks.com and www.MiningSectorStocks.com are research portals within the
InvestorIdeas.com content umbrella, featuring industry and stock news, exclusive articles and
financial columnists, audio interviews and podcasts, investor conferences, blogs, and a directory
of over 1200 mining stocks.

Gold and Mining Stocks: over 1200 listed stocks

Mining and Gold Stocks Directory - Global Mining and Gold Stocks Directory in PDF format lists
over 1200 publicly traded mining companies. Mining and metals investors can research gold and

mining stocks with the mining stocks directory, featuring Gold Stocks, Silver Stocks, Uranium
Stocks, Copper Stocks, Zinc Stocks and Precious Metals TSX, TSX Venture, OTC, NASDAQ,
AMEX, NYSE, ASX, AIM and other leading Stock Exchanges.
http://www.investorideas.com/Gold_Stocks/Stocks_List.asp

Sign up for the free investor news letter and get stock alerts in leading sectors!

http://www.investorideas.com/Resources/Newsletter.asp

About InvestorIdeas.com:
Investor Ideas is a global financial media online destination specialized in sector investing
content.

Disclosure: The following news is paid for and /or published as information only for our readers.
Running Fox Resource Corp. (TSX.V: RUN) for three days or press release services (seven
hundred)
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed
as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly,
but we offer no guarantees as to the accuracy of information presented. All Information relating to
featured companies is sourced from public documents and/ or the company and is not the opinion
of our web sites. This site is currently compensated by featured companies, news submissions
and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp

For Additional Information 800 665 0411 cvanzant@investorideas.com

Source – Investorideas.com
TSX Gold and Mining News; Running Fox Resource Corp. (TSX-V:RUN) New Mexico Project Drilling

Investorideas.com Mining Newswire - March 23, 2011
Steve Schurman, CEO, Director, reports: Running Fox Resources, (TSX-V:RUN) (US OTC:RFXRF) (FRANKFURT:C8Q)
The Company reports that diamond drilling has now started on a multi-hole drill program on Running Fox''s 100 % owned New Mexico project located south of Grants, New Mexico. Strategic Resources has optioned the property and is drilling to earn a 50 % interest, and may earn up to a 60 % interest upon delivery of a bankable mine feasibility study.
Running Fox also reports that its acquisition of the remaining 50 % of the Brett Gold and Silver Project is being finalized and Company plans to announce completion soon.
Running Fox (TSX-V:RUN) (US OTC:RFXRF) (FRANKFURT:C8Q) is a Canadian growth-oriented resource company with mineral projects including US uranium and Canadian gold properties, oil and gas assets, and oilfield service operations.
www.foxgold.ca
On Behalf of the Board of Directors, Steven Schurman
Running Fox Resource Corp.
1 604 725 8868
www.foxgold.ca
Investorideas.com news Disclosure: The following news is paid for and /or published as information only for our readers. Running Fox Resource Corp. (TSX.V: RUN) for three days or press release services (seven hundred)
Biodefense Stocks /Homeland Defense Stock Alert; Dynasil Corporation (NASDAQ GM:
DYSL) trading at $6.26, up 2.50 (66.49%)

Radiation Fears and Biological Warfare Threats Raise Investor Interest in Biodefense Stocks;
(OTCBB: AEMD), (NASDAQ GM: DYSL), (NYSE Amex: PIP), (NasdaqGM: SIGA )

Point Roberts, WA- March 23, 2011 - Investorideas.com, a leader in investor sector research
including Homeland Defense and Biodefense Stocks issues a trading alert on the sector as
Dynasil Corporation of America(NasdaqGM: DYSL ) becomes the top gainer on the NASDAQ on
patent news for its radiation monitoring device.

Dynasil Corporation (NASDAQ GM:DYSL), announced today that its research division, Radiation
Monitoring Devices, Inc. (RMD), also of Watertown, was granted additional U.S. patent claims for
advances in a detector material capable of responding independently to both neutron and gamma
radiation. This advancement is of critical national importance because the most commonly
available technology for detecting neutrons in Homeland Security applications, specifically
neutron detectors based on gaseous Helium-3, is becoming impractical because of serious
limitations on the availability of this gas.



In a recent article on Daily Finance entitled “Inside Wall Street: Looking to the Bio-Defense
Sector as Nuclear Fears Mount”, notes - The sector attracted a lot of interest after 9/11 and a
number of companies emerged to develop protective biodefense drugs and products. But with the
waning of dark headlines about terrorist threats, investors have tended to put them on their low-
priority list.
That may be about to change

Full article : http://www.dailyfinance.com/story/stock-picks/inside-wall-street-looking-to-bio-defense-sector-as-
nuclear-fea/19880106/

Biodefense Stocks Sector Snapshot
Aethlon Medical (OTCBB: AEMD) trading at $0.14
Dynasil Corporation (NASDAQ GM: DYSL) trading at $6.26, up 2.50 (66.49%) 12:21PM EDT
Emergent Biosolutions, Inc. Com (NYSE: EBS ) trading at $23.53, down 0.04 (0.17%) 12:29PM
EDT
PharmAthene, Inc. (NYSE Amex: PIP) trading at $3.42, up 0.01 (0.29%) 12:27PM EDT
Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) trading at $0.32
Siga Technologies (NasdaqGM: SIGA ) trading at $12.27, up 0.25 (2.08%) 12:29PM EDT

Research more Biodfense stocks at Investorideas.com
http://www.investorideas.com/bds/stock_list.asp

Biodefense Company Snapshot

Aethlon Medical (OTCBB: AEMD)
At Aethlon Medical, we create revolutionary devices to address infectious disease and cancer.
Our devices are designed to be novel platform solutions that fill therapeutic voids or aid in
disease diagnosis and monitoring.

Our Hemopurifier® is the first medical device to selectively target the removal of infectious
viruses and immunosuppressive proteins from the entire circulatory system. We recently
discovered that our Hemopurifier® captures tumor-secreted exosomes that suppress the immune
system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly
inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in
cancer care. By eliminating this mechanism, we believe our Hemopurifier® can fill an unmet
clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or
interaction risks to established and emerging treatment strategies.
More: www.aethlonmedical.com
Contacts:
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com

Visit the Aethlon Medical ( OTCBB:AEMD) showcase page on Investorideas.com
http://www.investorideas.com/CO/AEMD

Get added to the company’s news alerts:
http://www.investorideas.com/Resources/Newsletter.asp

About InvestorIdeas.com:

InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector
investing, including biotech stocks with its portal BiotechIndustryStocks.com.

Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make

recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our
sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated
by featured companies, news submissions and online advertising. AETHLON MEDICAL INC(OTC BB: AEMD )
Showcase biotech, biodefense and defense stock on Investorideas.com ( $one thousand five hundred per month, $five
thousand per month in 144 stock)Effective March 15, 2011
Aethlon Medical ( OTCBB:AEMD) :Certain of the statements herein may be forward-looking and involve risks and
uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and
other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially
different from any future results, performance, or achievements expressed or implied by the forward-looking statements.

800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com
Mining Stock Investor Alert for Katanga Mining Limited (TSX: KAT)

POINT ROBERTS, Wash., March23, 2011 - www.InvestorIdeas.com, a leader in sector research for investors, features a mining stock alert for Katanga Mining Limited (TSX: KAT), trading up at $1.77, up 0.23 (14.94%) in early morning trading, making it one of the top gainers.
Investorideas.com Newswire About Katanga Mining Limited
Katanga Mining Limited operates a major mine complex in the Democratic Republic of Congo producing refined copper and cobalt. The Company has the potential to become Africa's largest copper producer and the world's largest cobalt producer. Katanga is listed on the Toronto Stock Exchange under the symbol KAT. www.katangamining.com
Investorideas.com features investor research tools for mining investors including its stock directory, Mining stocks newswire and featured showcase mining stocks.
Subscribe to the mining newswire: http://www.investorideas.com/RSS/feeds/Gold-Mining-Stocks.xml
About our Mining Portals:
www.Gold-MiningStocks.com and www.MiningSectorStocks.com are research portals within the InvestorIdeas.com content umbrella, featuring industry and stock news, exclusive articles and financial columnists, audio interviews and podcasts, investor conferences, blogs, and a directory of over 1200 mining stocks.
Investorideas.com resource stock directories for investors:
Gold and Mining Stocks: over 1200 listed stocks
Mining and Gold Stocks Directory - Global Mining and Gold Stocks Directory in PDF format lists over 1200 publicly traded mining companies. Mining and metals investors can research gold and mining stocks with the mining stocks directory, featuring Gold Stocks, Silver Stocks, Uranium Stocks, Copper Stocks, Zinc Stocks and Precious Metals TSX, TSX Venture, OTC, NASDAQ, AMEX, NYSE, ASX, AIM and other leading Stock Exchanges.
http://www.investorideas.com/Gold_Stocks/Stocks_List.asp
Oil and Gas Stocks Directory - Global Oil and Gas Stocks Directory of Publicly traded oil and gas stocks listed on the TSX, TSX Venture, OTC, NASDAQ, AMEX, NYSE, ASX, AIM and other leading global Stock Exchanges. The comprehensive directory gives investors a full range and choice of micro cap to large cap stocks in the energy sector. The directory in PDF format, features hyperlinks to over 600 stocks symbol(s), company's URL and company's description.
Coal Stocks Directory - Global Directory of Publicly traded Coal stocks listed on the TSX, TSX Venture, OTC, NASDAQ, AMEX, NYSE, ASX, AIM, China and other leading global Stock Exchanges . The comprehensive directory gives investors a full range and choice of micro cap to large cap stocks in the coal sector, including clean coal and coking coal stocks. The directory in PDF format, features hyperlinks to coal stocks symbol(s), company's URL and company's description.
Natural Gas Stocks Directory - Global Directory of Publicly traded Natural Gas Stocks listed on the TSX, TSX Venture, OTC, NASDAQ, AMEX, NYSE, ASX, AIM and other leading global Stock Exchanges. The directory includes small cap, micro cap as well as large cap NYSE listed stocks for review. Natural gas stocks included range from LNG, Coal Bed Methane to exploration and producers in the sector. The directory in PDF format, features hyperlinks to stocks symbol(s), company's URL and company's description.
Investorideas.com members can access all energy stock directories, in addition to biotech, nanotech, water, defense and the newly added tech stocks for cloud computing and social network stocks.
Visit the Investor Ideas membership page to learn more at: http://www.investorideas.com/membership/
Sign up for the free investor news letter and get stock alerts in leading sectors! http://www.investorideas.com/Resources/Newsletter.asp
About InvestorIdeas.com:
Investor Ideas is a global financial media online destination specialized in sector investing content.
Disclosure: Investorideas.com was not compensated by Katanga Mining
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp
For Additional Information and or interest in becoming a content /revenue partner:
Dawn Van Zant: 800-665-0411 - dvanzant@investorideas.com
Source - Investorideas.com

Tuesday, March 22, 2011

Biodefense Stocks Snapshot; (OTCBB: AEMD), (NasdaqCM: CBLI), (NYSE Amex: PIP), (NasdaqGM: SIGA)

Point Roberts, WA - March 22, 2011 - Investorideas.com, a leader in investor sector research including biotech and biodefense stocks looks at some of the biotech stocks developing technologies and products to deal with news headlines of �radiation leaks and biological warfare�. Biodfense stocks have not been in the investor spotlight in recent years as Bioterrorism fears subsided and new issues took the forefront for Wall Street.
A major trigger for the sector are the global concerns and fears that Libyan leader, Colonel Muammar Gaddafi will potentially use biological and chemical weapons.
In a recent article on Daily Finance entitled "Inside Wall Street: Looking to the Bio-Defense Sector as Nuclear Fears Mount", notes - The sector attracted a lot of interest after 9/11 and a number of companies emerged to develop protective biodefense drugs and products. But with the waning of dark headlines about terrorist threats, investors have tended to put them on their low-priority list.
That may be about to change
Full article : http://www.dailyfinance.com/story/stock-picks/inside-wall-street-looking-to-bio-defense-sector-as-nuclear-fea/19880106/
Following 911, Project Bioshield Act was passed by Congress in 2004 calling for $5 billion for purchasing vaccines to be used in the event of a bioterrorist attack. Biotech companies continued to move forward with solutions as investors moved on to other sectors.
According to a recent article in Bioprepwatch.com, "Bioterrorism, in my view, is the most serious and likely threat to our national security, "Simon said, SNCTimes.com reports.
Full article : http://www.bioprepwatch.com/news/236579-expert-warns-of-bioterrors-ability-to-undermine-america
Chairman and CEO of Aethlon Medical, Inc.(OTCBB: AEMD) recently updated his shareholders regarding their biodfense efforts in letter March 15 th .
"As we advance our Hepatitis-C (HCV) treatment studies in India, we have also been active in our efforts to benefit from new government policies aimed at protecting U.S. civilian and military populations from bioterror and pandemic threats."
Mr. Joyce went on to say, :Earlier this year, we were honored to be invited by The Department of Health and Humans Services (HHS) to present our Hemopurifier® as a broad-spectrum platform technology to multi-agency health officials on January 12th at the Washington Convention Center. Since this presentation, our bioterror and pandemic threat initiative has led to follow-on meetings and presentations, including a formal presentation to the Biomedical Advanced Research and Development Authority (BARDA) on February 15th. "
PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, reported last month " that new pharmacokinetic data from the Company's Valortim® anthrax anti-toxin program were presented at the 9th Annual ASM Biodefense and Emerging Diseases Research Meeting, held in Washington, DC, February 6-9, 2011. The data were presented by Dr. Elizabeth Leffel, Director of Non-Clinical Sciences for PharmAthene, in a poster presentation entitled, "Pharmacokinetics of a Monoclonal Anthrax Anti-Toxin Antibody in Healthy and Infected Cynomolgus Macaques."
Biodefense Stocks Sector Snapshot
  • Aethlon Medical (OTCBB: AEMD) trading at $0.14
  • Cleveland BioLabs (NasdaqCM: CBLI ) trading at $7.35, up 0.19 (2.65%) 10:10AM EDT
  • Emergent Biosolutions, Inc. Com (NYSE: EBS ) trading at $23.59, up 0.02 (0.08%) 10:33AM EDT
  • PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, trading at $3.42, up 0.01 (0.29%) 10:31AM EDT
  • Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) trading at $0.33
  • Siga Technologies (NasdaqGM: SIGA ) trading at $11.83, down 0.28 (2.31%) 10:35AM EDT
  • Soligenix, Inc. (OTCBB:SNGX) trading at $0.20
Research more Biodfense stocks at Investorideas.com
http://www.investorideas.com/bds/stock_list.asp
Market Snapshot
  • Dow 12,027.75 -8.78 -0.07%
  • NASDAQ 2,690.32 -1.77 -0.07%
  • S&P 500 1,296.45 -1.93 -0.15%
  • 10 Yr Bond(%) 3.3390% +0.0160
  • Oil 102.45 +0.13 +0.13%
  • Gold 1,426.20 0.00 0.00
Biodefense Company Snapshot
Aethlon Medical ( OTCBB:AEMD)
At Aethlon Medical, we create revolutionary devices to address infectious disease and cancer. Our devices are designed to be novel platform solutions that fill therapeutic voids or aid in disease diagnosis and monitoring.
Our Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. We recently discovered that our Hemopurifier® captures tumor-secreted exosomes that suppress the immune system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in cancer care. By eliminating this mechanism, we believe our Hemopurifier® can fill an unmet clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or interaction risks to established and emerging treatment strategies.
More: www.aethlonmedical.com
Contacts:
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com
Visit the Aethlon Medical ( OTCBB:AEMD) showcase page on Investorideas.com
http://www.investorideas.com/CO/AEMD
Get added to the company's news alerts:
http://www.investorideas.com/Resources/Newsletter.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, including biotech stocks with its portal BiotechIndustryStocks.com.
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. AETHLON MEDICAL INC(OTC BB: AEMD ) Showcase biotech,  biodefense and defense stock on Investorideas.com ( $one thousand five hundred per month, $five thousand per month in 144 stock)Effective March 15, 2011     
Aethlon Medical ( OTCBB:AEMD) :Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements.  
800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com